A phase I/IIa dose escalation/expansion study to investigate the safety, tolerability, and efficacy of RZ-001 in HCC patients with no extrahepatic metastasis
Latest Information Update: 01 Nov 2022
At a glance
- Drugs RZ-001 (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2022 New trial record
- 10 Oct 2022 According to a Rznomics media release, company received Phase 1/2a IND approval of RZ-001 from the U.S FDA.